This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 04
  • /
  • Mateon Pharma submits IND to the FDA to approve ne...
Drug News

Mateon Pharma submits IND to the FDA to approve new phase II study of OT 101 for the treatment of COVID-19 pandemic.

Read time: 1 mins
Published:28th Apr 2020
Mateon Therapeutics Inc.announced it has submitted an Investigational New Drug (IND) application to the FDA)to study its investigational drug, OT-101, for the treatment of COVID-19 pandemic.The proposed randomized, double-blind, placebo-controlled Phase II study is intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia in the US. OT-101 is a potent inhibitor of SAR-CoV2 replication with efficacy and safety index on par or superior to Remdesivir- a Gilead’s drug. Unlike Remdesivir- OT-101 targets not only the virus replication but also the often lethal clinical sequelae of COVID-19, including pneumonia and fibrosis. OT-101 is a proprietary, first-in-class, TGF-beta antisense with broad efficacy against solid tumors including pancreatic cancer, glioblastoma, and melanoma across multiple phase II oncology trials. “We are advancing quickly the clinical development of OT-101 as multimodal drug against COVID-19. It is imperative to look at a basket of drug candidates to insure finding the cure for COVID-19. Additionally, an effective treatment for COVID-19 is more likely a cocktail of drugs,” said Dr Vuong Trieu, CEO of Mateon Therapeutics. “We look forward to collaborating closely with leading clinical investigators and the FDA to validate the effectiveness of OT-101 in treating COVID-19 in a controlled clinical setting.”
Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.